Skip to main content
logo
Danaher Corporation (DHR)
NYSE: DHR · Real-Time Price · USD
178.98
-1.64 (-0.91%)
At close: Apr 28, 2026, 4:00 PM EDT
179.06
+0.08 (0.04%)
Pre-market: Apr 29, 2026, 6:05 AM EDT

Revenue Breakdown

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
Biotechnology Revenue
7.48B7.29B6.76B
Biotechnology Revenue Growth
2.54%7.90%-5.76%
Life Sciences Revenue
7.39B7.33B7.33B
Life Sciences Revenue Growth
0.78%0.07%2.63%
Former Life Sciences Revenue
14.87B14.63B14.09B
Former Life Sciences Revenue Growth
1.65%3.83%-1.57%
Diagnostics Revenue
9.91B9.94B9.79B
Diagnostics Revenue Growth
-0.32%1.57%2.19%
Revenue (Other)
-14.87B-14.63B-14.09B
Revenue (Total)
24.78B24.57B23.88B
Revenue (Total) Growth
0.85%2.90%-0.06%

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
North America Revenue
10.25B10.36B10.30B
North America Revenue Growth
-1.00%0.59%3.35%
Western Europe Revenue
6.16B5.94B5.46B
Western Europe Revenue Growth
3.72%8.81%-0.20%
Other Developed Markets Revenue
1.26B1.25B1.25B
Other Developed Markets Revenue Growth
0.48%-0.08%-1.34%
High-Growth Markets Revenue
7.11B7.02B6.87B
High-Growth Markets Revenue Growth
1.24%2.21%-4.46%
Revenue (Total)
24.78B24.57B23.88B
Revenue (Total) Growth
0.85%2.90%-0.06%

Revenue Breakdown 2

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
Recurring Revenue
20.34B20.13B19.37B
Recurring Revenue Growth
1.07%3.93%3.66%
Non-Recurring Revenue
4.44B4.44B4.51B
Non-Recurring Revenue Growth
-0.11%-1.51%-13.42%
Revenue (Total)
24.78B24.57B23.88B
Revenue (Total) Growth
0.85%2.90%-0.06%

EBIT

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
Biotechnology Operating Income
1.96B1.86B1.69B
Biotechnology Operating Income Growth
4.99%10.62%-11.73%
Life Sciences Operating Income
544.00M520.00M879.00M
Life Sciences Operating Income Growth
4.61%-40.84%-27.30%
Former Life Sciences Operating Income
2.50B2.38B2.56B
Former Life Sciences Operating Income Growth
4.91%-7.02%-17.77%
Diagnostics Operating Income
2.61B2.65B2.63B
Diagnostics Operating Income Growth
-1.66%0.95%9.10%
Operating Income (Other)
-347.00M-344.00M-326.00M
Operating Income (Total)
4.76B4.69B4.86B
Operating Income (Total) Growth
1.49%-3.56%-6.52%

Key Performance Indicators

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
Core Sales Growth
2.00%-1.50%
Updated Apr 21, 2026. Data Source: Fiscal.ai.